Xeris Biopharma shares are trading lower after the company reported mixed Q2 financial results.benzinga_article·Aug 6 at 10:08 AMXERS+1.16%
Xeris Biopharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 92.1 MEarnings Watch·Aug 6 at 06:17 AMXERS+1.16%
Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 millionPUBT·Aug 6 at 06:14 AMXERS+1.16%
Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240PUBT·Aug 4 at 05:07 PMXERS+1.16%
Ligand Pharmaceuticals to report Q2 2026 results, host conference callPUBT·Jul 23 at 06:00 AMLGND-0.38%
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 | XERS Stock NewsStockTitan·Jul 22 at 10:30 PMXERS+1.16%
Xeris Biopharma CFO Steven Pieper disposes of 45,000 common shares worth $385,876.20PUBT·Jul 7 at 04:12 PMXERS+1.16%
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | XERS Stock NewsStockTitan·Jul 2 at 07:05 AMXERS+1.16%
